Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

NB003

GISTAR-1

Ningbo Newbay Technology Development · Phase 2/3 · Recruiting · Enrollment 255

NCT07379047

Catalyst Primary completion. 08.01.2028. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
NB003 15 mg BID (Part 1)3L GIST after imatinib and sunitinib15 mgITTregorafenib 160 mgn/r
Regorafenib 160 mg3L GIST160 mgITTn/rn/r

No efficacy figure is in this file for this study.